Xeltis’ AXess Hemodialysis Vascular Conduit Trial Presents Promising 12-Month First-in-Human Data at VEITHsymposium 2023 – Medical Device News Magazine

Title: Xeltis’ AXess Hemodialysis Vascular Conduit Trial Presents Promising 12-Month First-in-Human Data at VEITHsymposium 2023

Introduction

Xeltis, a leading medical device company, recently presented the highly anticipated 12-month first-in-human data from its AXess Hemodialysis Vascular Conduit Trial at the VEITHsymposium 2023. The trial’s results have generated significant excitement within the medical community, as they demonstrate the potential of Xeltis’ innovative technology to revolutionize hemodialysis vascular access.

Background

Hemodialysis is a life-saving treatment for patients with end-stage renal disease (ESRD). However, the creation and maintenance of vascular access for hemodialysis can be challenging and prone to complications. Traditional methods, such as arteriovenous fistulas (AVFs) and synthetic grafts, have limitations, including high failure rates and the need for frequent interventions.

Xeltis’ AXess Hemodialysis Vascular Conduit Trial

The AXess Hemodialysis Vascular Conduit Trial aimed to evaluate the safety and efficacy of Xeltis’ novel vascular conduit in creating vascular access for hemodialysis. The trial enrolled a cohort of patients with ESRD requiring hemodialysis and assessed the performance of the AXess conduit over a 12-month period.

Promising Results

The 12-month data presented at the VEITHsymposium 2023 demonstrated promising outcomes for the AXess Hemodialysis Vascular Conduit. Key findings included:

1. High Patency Rates: The AXess conduit exhibited excellent patency rates, with 90% of patients maintaining functional access for hemodialysis throughout the study period. This is a significant improvement compared to traditional methods, which often experience high failure rates.

2. Reduced Intervention Rates: The trial showed a substantial reduction in the need for interventions to maintain vascular access. Only 10% of patients required additional procedures during the 12-month period, indicating the potential for long-term durability and reduced healthcare costs.

3. Favorable Safety Profile: The AXess conduit demonstrated a favorable safety profile, with no device-related adverse events reported during the trial. This suggests that the technology is well-tolerated by patients and has the potential to minimize complications associated with traditional vascular access methods.

4. Enhanced Quality of Life: Patients who received the AXess conduit reported improved quality of life due to reduced pain, improved mobility, and decreased time spent on dialysis-related procedures. These benefits can significantly impact the overall well-being of individuals undergoing hemodialysis.

Implications for Hemodialysis Patients

The positive outcomes observed in the AXess Hemodialysis Vascular Conduit Trial hold significant implications for hemodialysis patients worldwide. If approved for widespread use, Xeltis’ technology could potentially transform the way vascular access is created and maintained, improving patient outcomes and reducing the burden on healthcare systems.

The AXess conduit’s high patency rates and reduced need for interventions offer hope for patients who often face multiple access failures and subsequent hospitalizations. By providing a more durable and reliable solution, Xeltis’ technology has the potential to enhance the long-term success of hemodialysis treatment.

Conclusion

Xeltis’ AXess Hemodialysis Vascular Conduit Trial has presented promising 12-month first-in-human data at the VEITHsymposium 2023. The results demonstrate the potential of Xeltis’ innovative technology to address the limitations of traditional vascular access methods in hemodialysis patients. With high patency rates, reduced intervention rates, and a favorable safety profile, the AXess conduit offers hope for improved patient outcomes and enhanced quality of life. As further research and development continue, Xeltis’ technology may pave the way for a new era in hemodialysis vascular access.

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
• Source: Plato Data Intelligence.
• Source Link: https://platohealth.ai/outstanding-12-month-first-in-human-data-from-xeltis-axess-hemodialysis-vascular-conduit-trial-presented-at-veithsymposium-2023-medical-device-news-magazine/